OMP-59R5

All ESMO 2014 abstracts with reference to OMP-59R5 are listed below

• 688P - Final results of a phase 1b of OMP-59R5 (anti-notch2/3/stem cell antibody) in combination with nab-paclitaxel and gemcitabine (Nab-P + Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC): ALPINE study
• 1473P - Phase 1b trial of anti-notch 2/3 antibody OMP-59R5 in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC): The PINNACLE study